Micturition syncope

Urovant Sciences® Receives “Best in Category” Award for Abstract Highlighting Investigational Novel Gene Therapy, URO-902, Presented at 2022 International Continence Society Conference

Retrieved on: 
Thursday, September 8, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Safety, Trial of the century, Medical school, Professor, Central European Time, Injection, Anatomy, Urinary urgency, CET, American Urological Association, Overactive bladder, Gesellschaft mit beschränkter Haftung, Patient, Female, Catheter, Urinary bladder, Department, Time in Europe, FDA, Beaumont Hospital, Abstract (summary), ICS, Beaumont, Cystoscopy, International Continence Society, Micturition syncope, NYSE, Urinary tract infection, Urination, Urinary incontinence, Science, Oakland University, Nocturia, OAB, BJU International, Urine, Pharmaceutical industry, Category, Urology, VideoRay UROVs

The award-winning abstract was presented at the 2022 International Continence Society annual meeting on September 8, 2022.

Key Points: 
  • The award-winning abstract was presented at the 2022 International Continence Society annual meeting on September 8, 2022.
  • The 2022 ICS Annual meeting is being held September 7-10, 2022, in a hybrid format with both online and in person participation (Vienna, Austria).
  • The podium presentation at ICS 2022 took place on Thursday, September 8, at 10:20 Central European Time (CET).
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting

Retrieved on: 
Friday, May 13, 2022
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, American Urological Association, Urination, Sex, Medicine, Urinary urgency, Urine, Sore throat, Overactive bladder, Vitamin, Neurogenic bladder dysfunction, Female, Nasal congestion, Urinary incontinence, Headache, Twitter, Science, Oakland University, Burden, Allergy, Nausea, Professor, Journal, Liver, Breast milk, Woman, Medical school, Beaumont, Vats, The Journal of Urology, Man, Urinary tract infection, Trial of the century, Diarrhea, NYSE, Department, Urinary retention, Catheter, Kopp, Digoxin, Doctor of Philosophy, I, Micturition syncope, Beaumont Hospital, Patient, OAB, Adult, FDA, Public health, LinkedIn, MD, Kidney, Upper respiratory tract infection, Population, Injection, Nocturia, Cystoscopy, Gesellschaft mit beschränkter Haftung, Safety, Pharmaceutical industry, Dietary supplement, Urology, Sexton

This was a prespecified, 12-week interim analysis of a 48-week multicenter, randomized, double-blind, placebo-controlled, dose-escalation study ( NCT04211831 ).

Key Points: 
  • This was a prespecified, 12-week interim analysis of a 48-week multicenter, randomized, double-blind, placebo-controlled, dose-escalation study ( NCT04211831 ).
  • Treatment-emergent adverse events occurred in 45.5% of patients receiving URO-902 24 mg, 46.2% receiving 48 mg, and 50.0% receiving placebo.
  • We are encouraged by these promising interim safety and efficacy findings for URO-902, said Sef Kurstjens, MD, PhD, Executive Vice President and Chief Medical Officer of Urovant Sciences.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo, GEMTESA, and the GEMTESA logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902

Retrieved on: 
Monday, March 7, 2022
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Sumitomo Dainippon Pharma, Upper respiratory tract infection, Patient, Adult, Medicine, Breast milk, Twitter, Sore throat, Doctor of Philosophy, Safety, Liver, LinkedIn, FDA, Kidney, Science, NYSE, Urinary incontinence, Headache, Nausea, Overactive bladder, American Urological Association, Urinary retention, Man, Vitamin, Allergy, Oakland University William Beaumont School of Medicine, Oakland University, Micturition syncope, Injection, Diarrhea, Beaumont Hospital, Female, Nasal congestion, MD, OAB, Digoxin, Urinary tract infection, Beaumont, Pharmaceutical industry, Fine chemical, Dietary supplement, Urology, the Phase 2a Study, URO-902, the Phase 2a Study, URO-902, THE PHASE 2A STUDY, URO-902

URO-902 has the potential to be the first gene therapy for patients with OAB.

Key Points: 
  • URO-902 has the potential to be the first gene therapy for patients with OAB.
  • The company plans to present the topline results of the study at the American Urological Association annual meeting being held May 13-16, 2022 in New Orleans, LA.
  • Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for areas of unmet need, with a dedicated focus in Urology.
  • The Companys second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.

Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg

Retrieved on: 
Monday, December 20, 2021
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Doctor of Philosophy, Urinary incontinence, Vibegron, OAB, FDA, American Urological Association, Urology, ICS, AUA, Overactive bladder, MD, Semantics, Advances in Therapy, Perception, Micturition syncope, SUNA, Pharmaceutical industry, Medical imaging, Patient, the Analysis, Overactive Bladder, GEMTESA®, Urovant Sciences, THE ANALYSIS, OVERACTIVE BLADDER, GEMTESA®, UROVANT SCIENCES

These significantly higher proportions of patients achieving pre-defined patient-perceived symptom improvements are likely to inform patients and providers in establishing realistic treatment goals.

Key Points: 
  • These significantly higher proportions of patients achieving pre-defined patient-perceived symptom improvements are likely to inform patients and providers in establishing realistic treatment goals.
  • The publication in a peer-reviewed journal is another example of Urovants commitment to informing the scientific medical community about meaningful effects of GEMTESA.
  • Although OAB is highly prevalent among adults; large clinical studies often neglect to report patient perceptions of the meaningfulness of symptom improvement.
  • The new publication describes a method to derive meaningful within-patient change using a patient-reported measure, the Patient Global Impression of Change (PGI-C).